Pharmafile Logo

Extavia

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

National Institute for Health and Care Excellence NICE logo

NICE gives final backing to drugs from Bayer, GSK and Otsuka

Eylea, Revolade and Abilify all recommended for NHS use

Biogen Idec building

Biogen Idec’s long-acting beta interferon moves ahead in MS

US and EU accept filings for long-acting multiple sclerosis drug Plegridy

- PMLiVE

NICE demands more data from Roche for MabThera in rare autoimmune disease

Unable to recommend expanding drug’s indication to include vasculitis

Biogen Idec building

Biogen Idec signs brain research deal with Edinburgh University

Will identify potential treatments for multiple sclerosis and motor neurone disease

Novartis building

Novartis lifts 2013 guidance on delay to Diovan generics

Reveals scale of payments to former CEO Daniel Vasella

National Institute for Health and Care Excellence NICE logo

Pfizer faces NICE rejection for cancer drug Bosulif

Draft guidance says drug is not cost-effective in chronic myeloid leukaemia

- PMLiVE

Revlimid faces NICE rejection for use in rare blood cancer

Watchdog's draft guidance does not recommend Celgene's drug for NHS use in England and Wales

Novartis sponsors rare disease patient community

Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)

- PMLiVE

Almirall launches Sativex in Italy

Brings cannabis-based drug for multiple sclerosis spasticity to market

- PMLiVE

Novartis enters developing nations vaccines partnership

Will work with Biological E to deliver vaccines for typhoid and paratyphoid A fevers

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis study

Phase III results show the antibody is more effective than Amgen/Pfizer's blockbuster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links